Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982 Feb;13(2):145–153. doi: 10.1111/j.1365-2125.1982.tb01349.x

Dosage adjustment in renal insufficiency.

G E Mawer
PMCID: PMC1402007  PMID: 7059411

Full text

PDF
145

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benjamin R. S., Riggs C. E., Jr, Bachur N. R. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res. 1977 May;37(5):1416–1420. [PubMed] [Google Scholar]
  2. Bjaeldager P. A., Jensen J. B., Larsen N. E., Hvidberg E. F. Elimination of oral cimetidine in chronic renal failure and during haemodialysis. Br J Clin Pharmacol. 1980 Jun;9(6):585–592. doi: 10.1111/j.1365-2125.1980.tb01084.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bloom P. M., Nelp W. B., Tuell S. H. Relationship of the excretion of tritiated digoxin to renal function. Am J Med Sci. 1966 Feb;251(2):133–144. doi: 10.1097/00000441-196602000-00002. [DOI] [PubMed] [Google Scholar]
  4. Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease. Drugs. 1978 Feb;15(2):93–131. doi: 10.2165/00003495-197815020-00002. [DOI] [PubMed] [Google Scholar]
  5. Brogden R. N., Speight T. M., Avery G. S. Sodium cromoglycate (cromolyn sodium): a review of its mode of action, pharmacology, therapeutic efficacy and use. Drugs. 1974;7(3):164–282. doi: 10.2165/00003495-197407030-00002. [DOI] [PubMed] [Google Scholar]
  6. Brogeden R. N., Speight T. M., Avery G. S. Amoxycillin: A review of its antibacterial and pharmacokinietic properties and therapeutic use. Drugs. 1975;9(2):88–140. doi: 10.2165/00003495-197509020-00002. [DOI] [PubMed] [Google Scholar]
  7. Dettli L. Individualization of drug dosage in patients with renal disease. Med Clin North Am. 1974 Sep;58(5):977–985. doi: 10.1016/s0025-7125(16)32094-6. [DOI] [PubMed] [Google Scholar]
  8. Drayer D. E. Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure. Clin Pharmacokinet. 1976 Nov-Dec;1(6):426–443. doi: 10.2165/00003088-197601060-00003. [DOI] [PubMed] [Google Scholar]
  9. Fabre J., Balant L. Renal failure, drug pharmacokinetics and drug action. Clin Pharmacokinet. 1976;1(2):99–120. doi: 10.2165/00003088-197601020-00002. [DOI] [PubMed] [Google Scholar]
  10. Faed E. M. Decreased clearance of diflunisal in renal insufficiency--an alternative explanation. Br J Clin Pharmacol. 1980 Aug;10(2):185–186. doi: 10.1111/j.1365-2125.1980.tb01744.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Faed E. M., McQueen E. G. Plasma half-life of clofibric acid in renal failure. Br J Clin Pharmacol. 1979 Apr;7(4):407–410. doi: 10.1111/j.1365-2125.1979.tb00956.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Flouvat B., Decourt S., Aubert P., Potaux L., Domart M., Goupil A., Baglin A. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. Br J Clin Pharmacol. 1980 Apr;9(4):379–385. doi: 10.1111/j.1365-2125.1980.tb01065.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gibson T. B., Nelson H. A. Drug kinetics and artificial kidneys. Clin Pharmacokinet. 1977 Nov-Dec;2(6):403–426. doi: 10.2165/00003088-197702060-00002. [DOI] [PubMed] [Google Scholar]
  14. Gilbert D. N., Sanford J. P. Methicillin: critical appraisal after a decade of experience. Med Clin North Am. 1970 Sep;54(5):1113–1125. [PubMed] [Google Scholar]
  15. Gyselynck A. M., Forrey A., Cutler R. Pharmacokinetics of gentamicin: distribution and plasma and renal clearance. J Infect Dis. 1971 Dec;124 (Suppl):S70–S76. doi: 10.1093/infdis/124.supplement_1.s70. [DOI] [PubMed] [Google Scholar]
  16. Hull J. H., Hak L. J., Koch G. G., Wargin W. A., Chi S. L., Mattocks A. M. Influence of range of renal function and liver disease on predictability of creatinine clearance. Clin Pharmacol Ther. 1981 Apr;29(4):516–521. doi: 10.1038/clpt.1981.72. [DOI] [PubMed] [Google Scholar]
  17. Kampmann J. P., Hansen J. M. Glomerular filtration rate and creatinine clearance. Br J Clin Pharmacol. 1981 Jul;12(1):7–14. doi: 10.1111/j.1365-2125.1981.tb01848.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kampmann J., Siersbaek-Nielsen K., Kristensen M., Hansen J. M. Rapid evaluation of creatinine clearance. Acta Med Scand. 1974 Dec;196(6):517–520. doi: 10.1111/j.0954-6820.1974.tb01053.x. [DOI] [PubMed] [Google Scholar]
  19. Mawer G. E., Lucas S. B., Knowles B. R., Stirland R. M. Computer-assisted prescribing of kanamycin for patients with renal insufficiency. Lancet. 1972 Jan 1;1(7740):12–15. doi: 10.1016/s0140-6736(72)90005-0. [DOI] [PubMed] [Google Scholar]
  20. Miller G. H., Arcieri G., Weinstein M. J., Waitz J. A. Biological activity of netilmicin, a broad-spectrum semisynthetic aminoglycoside antibiotic. Antimicrob Agents Chemother. 1976 Nov;10(5):827–836. doi: 10.1128/aac.10.5.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Myhill J. Investigation of the effect of data error in the analysis of biological tracer data. Biophys J. 2008 Dec 31;7(6):903–911. doi: 10.1016/S0006-3495(67)86628-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Orme B. M., Cutler R. E. The relationship between kanamycin pharmacokinetics: distribution and renal function. Clin Pharmacol Ther. 1969 Jul-Aug;10(4):543–550. doi: 10.1002/cpt1969104543. [DOI] [PubMed] [Google Scholar]
  23. Pinder R. M., Brogden R. N., Sawyer P. R., Speight T. M., Avery G. S. Metoclopramide: a review of its pharmacological properties and clinical use. Drugs. 1976;12(2):81–131. doi: 10.2165/00003495-197612020-00001. [DOI] [PubMed] [Google Scholar]
  24. Reidenberg M. M. The biotransformation of drugs in renal failure. Am J Med. 1977 Apr;62(4):482–485. doi: 10.1016/0002-9343(77)90401-6. [DOI] [PubMed] [Google Scholar]
  25. Reuning R. H., Sams R. A., Notari R. E. Role of pharmacokinetics in drug dosage adjustment. I. Pharmacologic effect kinetics and apparent volume of distribution of digoxin. J Clin Pharmacol New Drugs. 1973 Apr;13(4):127–141. doi: 10.1002/j.1552-4604.1973.tb00074.x. [DOI] [PubMed] [Google Scholar]
  26. Riegelman S., Loo J. C., Rowland M. Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. J Pharm Sci. 1968 Jan;57(1):117–123. doi: 10.1002/jps.2600570123. [DOI] [PubMed] [Google Scholar]
  27. Rietbrock N., Guggenmos J., Kuhlmann J., Hess U. Bioavailability and pharmacokinetics of beta-methyldigoxin after multiple oral and intravenous doses. Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):373–379. doi: 10.1007/BF00606551. [DOI] [PubMed] [Google Scholar]
  28. Sheiner L. B., Halkin H., Peck C., Rosenberg B., Melmon K. L. Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentrations. Ann Intern Med. 1975 May;82(5):619–627. doi: 10.7326/0003-4819-82-5-619. [DOI] [PubMed] [Google Scholar]
  29. Spring P. Calculation of drug dosage regimens in patients with renal disease: a new nomographic method. Int J Clin Pharmacol Biopharm. 1975 Jan;11(1):76–80. [PubMed] [Google Scholar]
  30. Steiness E. Renal tubular secretion of digoxin. Circulation. 1974 Jul;50(1):103–107. doi: 10.1161/01.cir.50.1.103. [DOI] [PubMed] [Google Scholar]
  31. Talseth T. Clinical pharmacokinetics of hydrallazine. Clin Pharmacokinet. 1977 Sep-Oct;2(5):317–329. doi: 10.2165/00003088-197702050-00001. [DOI] [PubMed] [Google Scholar]
  32. Tucker G. T. Measurement of the renal clearance of drugs. Br J Clin Pharmacol. 1981 Dec;12(6):761–770. doi: 10.1111/j.1365-2125.1981.tb01304.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Vree T. B., Hekster Y. A., Damsma J. E., van Dalen R., Hafkenscheid J. C., Friesen W. T. Renal excretion of sulphamethoxazole and its metabolite N4-acetylsulphamethoxazole in patients with impaired kidney function. Ther Drug Monit. 1981;3(2):129–135. doi: 10.1097/00007691-198102000-00003. [DOI] [PubMed] [Google Scholar]
  34. Wan S. H., Koda R. T., Maronde R. F. Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Br J Clin Pharmacol. 1979 Jun;7(6):569–574. doi: 10.1111/j.1365-2125.1979.tb04644.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES